Recent

% | $
Quotes you view appear here for quick access.

Protalix BioTherapeutics, Inc. (PLX) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • mountainmansmith mountainmansmith Feb 22, 2011 8:19 PM Flag

    New Website Design

    From the new website:

    Strategy
    Protalix is a leading biologic drug company with a next-generation expression technology, ProCellEx, to access the exploding area of biosimilars, biobetters and novel biologics – a potential market of $125+ billion. The ProCellEx platform technology potentially offers significant advantages over existing expression systems, including cost effectiveness, safety and entry into certain patent-protected markets.

    125 Billion!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • You must have lost a decimal point.

      The first drug, waiting for approval this week, is targeting a $1.25B (not 125) market.

      Adjust your expectations. There will be no $1B yearly revenues from this drug:

      1. - We are not going to take 100% of the market. Shire and Sanofi/Genzime will find ways to retain varying percentages of their respective patient bases. There are going to be three players, no one takes all.

      2. - We are going to be cheaper than the other players (good for the patients and the insurers). The size of the market will shrink accordingly.

      3. - Pfizer will take 60% of the revenues from sales outside of Israel.

      Our CEO is Dr. "David" (not yet "Goliath") Aviezer.

      The approval of the Gaucher drug will only open a tap. The big flood will come later, as the pipeline comes to age.

 
PLX
1.64+0.05(+3.14%)Jul 31 4:03 PMEDT